Furiex Pharmaceuticals Company Profile (NASDAQ:FURX)

About Furiex Pharmaceuticals

Furiex Pharmaceuticals logoFuriex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Life Sciences Tools & Services
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ
  • Symbol: FURX
  • CUSIP: 36106P10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $
  • 200 Day Moving Average: $
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: 99.78
  • P/E Growth:
  • Market Cap: $
Additional Links:
Companies Related to Furiex Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Furiex Pharmaceuticals (NASDAQ:FURX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Furiex Pharmaceuticals (NASDAQ:FURX)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Furiex Pharmaceuticals (NASDAQ:FURX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2014Q114($0.63)($1.25)$10.01 million$6.40 millionViewN/AView Earnings Details
3/11/2014Q413($1.06)($0.63)$12.80 million$13.10 millionViewN/AView Earnings Details
11/5/2013Q313($1.33)($0.85)$13.17 million$15.55 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.65)($2.32)$11.94 million$3.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.70$0.82$33.42 million$39.33 millionViewN/AView Earnings Details
3/6/2013Q4 2012($2.04)($0.90)$7.43 million$9.21 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Furiex Pharmaceuticals (NASDAQ:FURX)
Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $1.05 EPS


Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Furiex Pharmaceuticals (NASDAQ:FURX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2014Paul S CovingtonVPSell10,368$104.12$1,079,516.16View SEC Filing  
6/24/2014Sailash PatelCFOSell32,928$104.00$3,424,512.00View SEC Filing  
6/18/2014Paul S CovingtonVPSell45,691$104.11$4,756,890.01View SEC Filing  
6/17/2014Gail Frances McintyreSVPSell74,457$105.01$7,818,729.57View SEC Filing  
6/13/2014Paul S CovingtonVPSell3,228$104.25$336,519.00View SEC Filing  
6/10/2014Gail Frances McintyreSVPSell1,746$104.58$182,596.68View SEC Filing  
6/10/2014Paul S CovingtonVPSell2,872$104.63$300,497.36View SEC Filing  
6/10/2014Sailash PatelCFOSell1,504$104.68$157,438.72View SEC Filing  
9/10/2013Paul S CovingtonVPSell30,000$40.89$1,226,700.00View SEC Filing  
8/9/2013Peter CorrDirectorSell7,500$39.74$298,050.00View SEC Filing  
7/19/2013Gail Frances McintyreSVPSell10,581$40.00$423,240.00View SEC Filing  
3/12/2013Stephen W KaldorDirectorSell6,352$41.58$264,116.16View SEC Filing  
8/15/2012June Sherie AlmenoffPresidentBuy1,000$18.67$18,670.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headlines for Furiex Pharmaceuticals (NASDAQ:FURX)
No headlines for this company have been tracked by MarketBeat.com


Furiex Pharmaceuticals (NASDAQ:FURX) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by MarketBeat.com Staff